SCHEMBL3427282

SCHEMBL3427282

C=Cc1cnc(Nc2ccc(N3CCOCC3)cc2OC)cc1Nc1ccccc1C(=O)NC

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 10/20 0.80
MAPK9 P45984 7/20 0.80
PTK2 Q05397 10/20 0.76
CDC7 O00311 1/20 0.67
PLK4 O00444 1/20 0.67
CHEK1 O14757 1/20 0.67
AURKA O14965 1/20 0.67
DCLK1 O15075 1/20 0.67
PDPK1 O15530 1/20 0.67
DAPK3 O43293 1/20 0.67
DYRK3 O43781 1/20 0.67
JAK2 O60674 1/20 0.67
PRKD3 O94806 1/20 0.67
PAK4 O96013 1/20 0.67
CHEK2 O96017 1/20 0.67
EGFR P00533 1/20 0.67
ERBB2 P04626 1/20 0.67
PRKCG P05129 1/20 0.67
INSR P06213 1/20 0.67
LCK P06239 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770344 0.90 MAPK10 (0.83) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL1232876 0.89 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL1232888 0.89 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL13061082 0.89 MAPK10 (0.82) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL13060635 0.89 MAPK10 (0.82) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL1230956 0.89 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL12886508 0.87 MAPK10 (0.80) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL3781231 0.87 MAPK10 (0.80) MAPK10MAPK9PTK2CDC7PLK4
SCHEMBL1232887 0.87 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4
Vs-4718 SCHEMBL29478885 0.87 MAPK10 (1.00) MAPK10MAPK9PTK2CDC7PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2010-12-16 US disclosed
EP-2249650-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK GlaxoSmithKline LLC (US) 2010-11-17 EP disclosed
WO-2009105498-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 WO disclosed
WO-2009105498-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK SMITHKLINE BEECHAM CORPORATION (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317663-A1 ANILINOPYRIDINES AS INHIBITORS OF FAK PTK2, JAK2, SRC MAPK10 386/4885MAPK9 173/4885PTK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.